The aryl hydrocarbon receptor complex and the control of gene expression

Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
Critical Reviews in Eukaryotic Gene Expression (Impact Factor: 2.39). 02/2008; 18(3):207-50. DOI: 10.1615/CritRevEukarGeneExpr.v18.i3.20
Source: PubMed

ABSTRACT The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that controls the expression of a diverse set of genes. The toxicity of the potent AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin is almost exclusively mediated through this receptor. However, the key alterations in gene expression that mediate toxicity are poorly understood. It has been established through characterization of AhR-null mice that the AhR has a required physiological function, yet how endogenous mediators regulate this orphan receptor remains to be established. A picture as to how the AhR/ARNT heterodimer actually mediates gene transcription is starting to emerge. The AhR/ARNT complex can alter transcription both by binding to its cognate response element and through tethering to other transcription factors. In addition, many of the coregulatory proteins necessary for AhR-mediated transcription have been identified. Cross talk between the estrogen receptor and the AhR at the promoter of target genes appears to be an important mode of regulation. Inflammatory signaling pathways and the AhR also appear to be another important site of cross talk at the level of transcription. A major focus of this review is to highlight experimental efforts to characterize nonclassical mechanisms of AhR-mediated modulation of gene transcription.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Summarized recent data on the polymorphism of the xenobiotic metabolism and detoxification enzyme (XMDE) system in humans are presented. The current notions on the molecular mechanisms of metabolic processes and the role of genetic polymorphism are reviewed. The roles of transport proteins and nuclear receptors in the regulation of the activity of the XMDE system are shown. The possibilities of using the polymorphism of the XMDE system as the basis for predicting the risk of oncological diseases are considered. Experimental modeling of different levels of the epoxide synthetase and epoxide hydratase activities revealed their close relationship with the toxic, mutagenic, and carcinogenic actions of polycyclic aromatic hydrocarbons. The data indicating the necessity of considering the physiological factors that could influence xenobiotic metabolism and the development of pathological changes are given. Keywordspolymorphism-xenobiotic metabolism and detoxification enzyme system-epoxide synthetase-epoxide hydratase-physiological factors
    Human Physiology 11/2010; 36(6):723-736. DOI:10.1134/S0362119710060149
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: High blood pressure and endothelial dysfunction are two systemic abnormalities of the cardiovascular system that extensively contribute to the etiology of cardiovascular diseases, which represent the number one killer in the United States for decades and become more severe in developing countries. Previous studies have indicated that aryl hydrocarbon receptor (AHR), a transcription factor primarily mediating xenobiotic metabolism, plays an important role in cardiovascular development and physiology. AHR deficient mice have been demonstrated to develop hypotension at sea level and oxygen-dependent, endothelin-1 (ET-1) mediated hypertension at mild altitude. However, after generations at mild altitude, AHR deficient mice appear to acclimate to the lower atmospheric partial pressure of oxygen and exhibit normal levels of ET-1 and hypotension. Therefore, the goal of my research was to elucidate the mechanism by which endogenous AHR regulates blood pressure by studying blood pressure regulation in the absence of the AHR. I found that AHR deficient mice exhibit significantly lower systemic arterial blood pressure, dysregulated circadian blood pressure rhythm, and significantly elevated vascular endothelial nitric oxide synthase (eNOS) expression and systemic production of nitric oxide (NO). I found that treating AHR deficient mice with the NOS inhibitor, Nω-nitro-L-arginine (LNNA) failed to normalize blood pressure, suggesting that vascular eNOS over expression may not be the primary mediating factor of hypotension in AHR knockout mice. Further investigation on vascular activity ex vivo indicated increased sensitivity of vascular smooth muscle to NO which may simultaneously contribute to the hypotension in this scenario. In vitro studies using human aortic endothelial cells with AHR expression knockdown by siRNA suggested an intracellular role of endogenous AHR signaling in suppressing eNOS mRNA expression, which could be normalized by exogenous ligand activation of the residual AHR. My results suggest that AHR suppresses eNOS expression and acts to maintain basal vascular tone and normal blood pressure. Therefore, therapeutic approaches that antagonize AHR signaling could improve NO bioavailability and benefit patients with hypertension and vascular diseases commonly associated with endothelial dysfunction. Biomedical Sciences Doctoral University of New Mexico. Biomedical Sciences Graduate Program Walker, Mary Kanagy, Nancy Resta, Tom Timmins, Graham
  • Source
Show more


Available from